---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062005"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:27:22.067305+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences reports Q3 2023 net loss $7.1M; cash $20M; advances cytisinicline trials

## Summary
- Cash and restricted cash $20.0M as of Sep 30, 2023; net loss $7.1M in Q3 2023.
- ORCA-2 Phase 3 smoking cessation results published in JAMA; cytisinicline showed significant efficacy.
- Completed dosing of three NDA-supportive studies (QT, PK in smokers, renal impairment); data due early 2024.
- Phase 2 ORCA-V1 results presented: 2.6-fold increase in vaping cessation odds vs placebo.
- Shares outstanding: 21,165,760 as of Nov 9, 2023.

## SEC filing metadata
- accession: 0000950170-23-062005
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/0000950170-23-062005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/achv-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062005
- JSON: https://secwatch.observer/filing/0000950170-23-062005.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062005.txt

## Key facts
- Earnings Releases
  ACHIEVE LIFE SCIENCES, INC. reported third quarter 2023 results: net income Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively..
  - Period: third quarter 2023
  - Net income: Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively.
  - Result: reported results
  source text: Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000095017023062005/0000950170-23-062005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.